Image of Antibody Mediated Remyelination

CNS inflammatory demyelinating disorders affect at least 400,000 patients in the United States and account for the most common disabling neurological diseases of young adults. More than 50 percent of patients are significantly disabled. More than 1,500 new patients with these disorders come to Mayo Clinic annually.

This Center comprises an established interactive interdisciplinary, multi-campus infrastructure promoting basic science research into the mechanisms of demyelination and remyelination, implementing new discoveries into clinical trials, and advancing the care and treatment of patients with MS and related inflammatory demyelinating disorders. The Center extends beyond clinical neurologists to encompass the expertise of clinicians and scientists in neuroscience, immunology, radiology, physical medicine and rehabilitation, genetics, pathology, biochemistry, pediatrics and laboratory medicine.

By focusing and strengthening the full spectrum of research — from basic studies to clinical applications — this Center will enhance the care we provide to Mayo's increasing census of patients with MS and related disorders.

The Center's goal is to develop novel treatments for patients who have CNS disorders characterized by inflammatory and demyelinating pathology. The convergence of basic science research and exceptional clinical expertise, which is the Mayo tradition, is the surest guarantee that these disorders will ultimately be cured and prevented.